HER2 Support Group Forums - View Single Post

Susan2 · 05-25-2006, 05:00 AM

It took me a few times to read this looking up the various words as I read it. In reading this, it sounds like that there are 2 issues. One being that some tumors are hypoxic (oxygen deprived) and the second is that the LOX enzyme overexpression (produced by hypoxic tumors) is a growth agent for metasis.

If this is an accurate interpretation, then there would appear to be 2 possibilities for combating it. One would be to oxygenate the tumor. I believe that clinical trials are underway by Allos with efaproxirale to do this. The premise being that hypoxic tumors do not respond to chemo or radiation as well as oxygenated tumors. The second would be a LOX inhibitor. (The last sentence says that LOX would be a therapeutic agent; did that mean a LOX inhibitor?)

Is this how you interpret this?

Thanks for finding this. I am learning far more about this than I ever wanted to.

05-25-2006, 05:00 AM	#5
Susan2 Senior Member Join Date: Mar 2006 Posts: 87	It took me a few times to read this looking up the various words as I read it. In reading this, it sounds like that there are 2 issues. One being that some tumors are hypoxic (oxygen deprived) and the second is that the LOX enzyme overexpression (produced by hypoxic tumors) is a growth agent for metasis. If this is an accurate interpretation, then there would appear to be 2 possibilities for combating it. One would be to oxygenate the tumor. I believe that clinical trials are underway by Allos with efaproxirale to do this. The premise being that hypoxic tumors do not respond to chemo or radiation as well as oxygenated tumors. The second would be a LOX inhibitor. (The last sentence says that LOX would be a therapeutic agent; did that mean a LOX inhibitor?) Is this how you interpret this? Thanks for finding this. I am learning far more about this than I ever wanted to.